End Price Gouging for Insulin Act

House Bill 5364 - End Price Gouging for Insulin Act: Overview, Status, and Impact

Hozzl · 2022-10-28T01:46:01Z

Explore the details of House Bill 5364 End Price Gouging for Insulin Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

10/28/2022, 1:46 AM

Congressional Summary of HR 5364

End Price Gouging for Insulin Act

This bill requires the Department of Health and Human Services to set a maximum price for insulin products for individuals and enrollees of federal health programs.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 5364

Bill HR 5364 is currently in the status of Bill Introduced since December 9, 2019. Bill HR 5364 was introduced during Congress 116 and was introduced to the House on December 9, 2019. Bill HR 5364's most recent activity was Referred to the Subcommittee on Health. as of January 14, 2020

Bipartisan Support of Bill HR 5364

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 5364

Primary Policy Focus

Health

Potential Impact Areas

- Asia

- Australia

- Canada

- Department of Health and Human Services

- Europe

- Executive agency funding and structure

- France

- Germany

- Health care costs and insurance

- Health programs administration and funding

- Indian social and development programs

- Inflation and prices

- Italy

- Japan

- Medicaid

- Medical research

- Medicare

- Netherlands

- North America

- Prescription drugs

- Research administration and funding

- Research and development

- Retail and wholesale trades

- Spain

- Sweden

- Switzerland

- United Kingdom

- Veterans' medical care

Alternate Title(s) of Bill HR 5364

End Price Gouging for Insulin Act

To require the Secretary of Health and Human Services to establish an annual reference price for insulin products for purposes of Federal health programs, and for other purposes.

End Price Gouging for Insulin Act